Medical treatment of hirsutism in women

Current Medicinal Chemistry

Volumn 17, Issue 23, 2010, Pages 2530-2538

  Lumachi, F ^a   Basso, S M M ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

antiandrogens; cyproterone acetate; Hirsutism; hyperandrogenism; hypertricosis; oral contraceptives; spironolactone

Indexed keywords

ANDROGEN; COSMETIC; CYPROTERONE ACETATE; DIENOGEST; DROSPIRENONE; EFLORNITHINE; FINASTERIDE; FLUTAMIDE; METFORMIN; ROSIGLITAZONE; SPIRONOLACTONE; TRIPTORELIN;

ABSENCE OF SIDE EFFECTS; ANDROGEN METABOLISM; ARTICLE; CLINICAL FEATURE; CUSHING SYNDROME; DIABETES MELLITUS; DRUG BINDING; DRUG EFFICACY; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG TOLERABILITY; FEMALE; HAIR GROWTH; HEADACHE; HIRSUTISM; HUMAN; HYPOTENSION; INSULIN SENSITIVITY; METABOLIC DISORDER; PATHOPHYSIOLOGY; PATIENT SATISFACTION; POLYURIA; PSYCHOSOCIAL CARE; REPRODUCTION; RISK FACTOR; THYROID DISEASE;

ANDROGEN ANTAGONISTS; CONTRACEPTIVES, ORAL; CYPROTERONE ACETATE; ESTROGENS; FEMALE; HAIR REMOVAL; HIRSUTISM; HUMANS; PROGESTINS; SPIRONOLACTONE;

EID: 77955652371     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710791556005     Document Type: Article

References (78)

1. Rittmaster, R. Medical treatment of androgen-dependent hirsutism. J. Clin. Endocrinol. Metab., 1995, 80, 2559-2563.
2. Lumachi, F.; Rondinone, R. Use of cyproterone acetate, finasteride, and spironolactone to treat idiopathic hirsutism. Fertil. Steril., 2003, 79, 942-946.
3. Cosma, M.; Swiglo, B.A.; Flynn, D.N.; Kurtz, D.M.; LaBelle, M.L.; Mullan, R.J.; Erwin, P.J.; Montori, V.M. Clinical review: Insulin sensitizers for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials. J. Clin. Endocrinol. Metab., 2008, 93, 1135-1142.
4. Sonino, N.; Fava, G.A.; Mani, E.; Belluardo, P.; Boscaro, M. Quality of life of hirsute women. Postgrad. Med., 1993, 69, 186-189.
5. Azziz, R. The evaluation and management of hirsutism. Obstet. Gynecol., 2003, 101, 995-1007.
6. Lincoln, S.R. Androgens excess diagnosis. In Clinical Reproductive Medicine, Cowan, B.D.; Seifer, D.B., Eds.; Lippincott-Raven: Philadelphia, 1997; pp. 95-101.
7. Elghblawi, E. Idiopatic hirsutism: excessive bodily and facial hair in women. Br. J. Nurs., 2008, 17, 192-7.
8. Ebling, F.J. Hair. J. Invest. Dermatol., 1976, 67, 98-105.
9. Azziz, R.; Carmina, E.; Sawaya, M.E. Idiopathic hirsutism. Endocr. Rev., 2000, 21, 347-362.
10. Schoemeker, J. Hirsutism. In Endocrinology and Metabolism, Pinchera, A., Ed.; McGraw-Hill: London, 2001; pp. 569-572.
11. Jankovic, S.M.; Jankovic, S.V. The control of hair growth. Dermatol. Online J., 1998, 4, 2-6.
12. Rosenfield, R.L. Clinical practice. Hirsutism. N. Engl. J. Med., 2005, 353, 2578-2588.
13. Goldfien, A. Ovaries. In Basic & Clinical Endocrinology, Greenspan, F.S.; Gardner, D.G., Eds.; Lange Medical Book/McGraw Hill: New York, 2001: pp. 453-508.
14. Lumachi, F.; Zulian, E.; Scaroni, C. Cost-effective therapy in patients with idiopathic hirsutism. Expert Rev. Pharmacoecon. Outcomes Res., 2004, 4, 297-306.
15. Findling, J.W.; Aron, D.C.; Tyrrell, J.B. Glucocorticoids & adrenal androgens. In Basic & Clinical Endocrinology, Greenspan, F.S.; Strewler, G.J., Eds.; Appleton Lange: Stamford, 1997; pp. 317-358.
16. Brown, J.; Farquhar, C.; Lee, O.; Toomath, R.; Jepson, R.G. Spironolactone varsus placebo or in combination with steroids for hirsutism and/or acne. Cochrane Database Syst. Rev., 2009, 4, CD000194.
17. Ferriman, D.; Gallwey, J.D. Clinical assessment of body hair growth in women. J. Clin. Endocrinol. Metab., 1961, 21, 1440-1447.
18. Blume-Peytavi, U.; Hahn, S. Medical treatment of hirsutism. Dermatol. Ther., 2008, 21, 329-339.
19. Martin, K.A.; Chang, R.J.; Ehrmann, D.A.; Ibanez, L.; Lobo, R.A.; Rosenfield, R.L.; Shapiro, J.; Montori, V.M.; Swiglo, B.A. Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab., 2008, 93, 1105-1120.
20. Koulouri, O.; Conway, G.S. Management of hirsutism. BMJ, 2009, 338, 823-826.
21. Olsen, E.A. Methods of hair removal. J. Am. Acad. Dermatol., 1999, 40, 143-155.
22. Liew, S.H. Unwanted body hair and its removal: a review. Dermatol. Surg., 1999, 25, 431-439.
23. Haedersdal, M.; Egekvist, H.; Efsen, J.; Bjerring, P. Skin pigmentation and texture changes after hair removal with the normal-mode ruby laser. Acta Dermato-Venereol., 1999, 79, 465-468.
24. Wagner, R.F. jr.; Brysk, H.; Tyring, S.K. Revisiting the Michel/Green controversy of 1879: was Carron du Villards the first to use probe/needle electrolysis for permanent hair destruction? Int. J. Dermatol., 1997, 36, 947-951.
25. Richards, R.N.; Meharg, G.E. Electrolysis: observations from 13 years and 140,000 hours of experience. J. Am. Acad. Dermatol., 1995, 33, 662-666.
26. Richards, R.N.; McKenzie, M.A.; Meharg, G.E. Electroepilation (electrolysis) in hirsutism. 35,000 hours' experience on the face and neck. J. Am. Acad. Dermatol., 1986, 15, 693-697.
27. Nouri, K.; Vejjabhinanta, V.; Patel, S.S.; Singh, A. Photoepilation: a growing trend in laser-assisted cosmetic dermatology. J. Cosmet. Dermatol., 2008, 7, 61-67.
28. Al Robaee, A.; Al-Zolibani, A.; Al-Shobaili A.; Aslam, A. Update on Hirsutism. Acta Dermatovenerol. Alp Panonica Adriat., 2008, 17, 103-119.
29. Loo, W.J.; Lanigan, S.W. Laser treatment improves quality of life of hirsute females. Clin. Exp. Dermatol., 2002, 27, 439-441.
30. Haedersdal, M.; Gøtzsche, P.C. Laser and photoepilation for unwanted hair growth. Cochrane Database Syst. Rev., 2006, 4, CD004684.
31. Rajpar, S.F.; Hague, J.S.; Abdullah, A.; Lanigan, S.W. Hair removal with the long-pulse alexandrite and long-pulse Nd:YAG lasers is safe and well tolerated in children. Clin. Exp. Dermatol., 2009, 34, 684-687.
32. Lanigan, S.W. J. Incidence of side effects after laser hair removal. Am. Acad. Dermatol., 2003, 49, 882-886.
33. Hussain, M.; Polnikorn, N.; Goldberg, D.J. Laser-assisted hair removal in Asian skin: efficacy, complications, and the effect of single versus multiple treatments. Dermatol. Surg., 2003, 29, 249-254.
34. Balfour, J.A.; McClellan, K. Topical eflornithine. Am. J. Clin. Dermatol., 2001, 2, 197-201.
35. Wolf, J.E.Jr.; Shander, D.; Huber, F.; Jackson, J.; Lin, C.S.; Mathes, B.M.; Schrode, K. Randomized, double-blind clinical evaluation of the efficacy and safety of topical eflornithine HCl 13.9% cream in the treatment of women with facial hair. Int. J. Dermatol., 2007, 46, 94-98.
36. Smith, S.R.; Piacquadio, D.J.; Beger, B.; Littler, C. Eflornithine cream combined with laser therapy in the management of unwanted facial hair growth in women: a randomized trial. Dermatol. Surg., 2006, 32, 1237-1243.
37. Koulouri, O.; Conway, G.S. A systematic review of commonly used medical treatments for hirsutism in women. Clin. Endocrinol., 2008, 68, 800-805.
38. Darney, P.D. The androgenity of progestins. Am. J. Med., 1995, 98, 104S-110S.
39. Batukan, C.; Müderris, I.I. Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism. Fertil. Steril., 2006, 85, 436-440.
40. Kaplan, B. Desogestrel, norgestimate, and gestodene: the newer progestins. Ann. Pharmacother., 1995, 29, 736-742.
41. Taner, C.; Inal, M.; Baβogul, O.; Onoglu, A.; Karanfil, C.; Tinal, S.; Ispahi, C. Antiandrogens fort he treatment of hursutism: a systematic review and mataanalysises of randomized controlled trials. Gynecol. Obstet. Invest., 2002, 54, 105-108.
42. Swiglo, B.A.; Cosma, M.; Flynn, D.N.; Kurtz, D.M.; LaBella, M.L.; Mullan, R.J.; Erwin, P.J.; Montori, V.M. Clinical review: Antiandrogens for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials. J. Clin. Endocrinol. Metab., 2008, 93, 1153-1160.
43. Van der Spuy, Z.M.; Le Roux, P.A.; Matjila, M.J. Cyproterone acetate for hirsutism. Cochrane Database Syst. Rev., 2003, 4, CD001125.
44. Venturoli, S.; Marescalchi, O.; Colombo, F.M.; Macrelli, S.; Ravaioli, B.; Bagnoli, A.; Paradisi, R.; Flamigni, C. A prospective randomized trial comparing low dose flutamide, finasteride, ketoconazole, and cyproterone acetate-estrogen regimens in the treatment of hirsutism. J. Clin. Endocrinol. Metab., 1999, 84, 1304-1310.
45. Kokaly, W.; McKenna, T.J. Relapse of hirsutism following longterm successful treatment with oestrogen-progestogen combination. Clin. Endocrinol., 2000, 52, 379-382.
46. Vasilakis-Scaramozza, C.; Jick, H. Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives. Lancet, 2001, 358, 1427-149.
47. Raudrant, D.; Rabe, T. Progestogens with antiandrogenic properties. Drugs, 2003, 63, 463-492.
48. Foster, R.H.; Wilde, M.I. Dienogest. Drugs, 1998, 56, 825-835.
49. McMullen, G.R.; Van Herle, A.J. Hirsutism and the effectiveness of spironolactone in its management. J. Endocrinol. Invest., 1993, 16, 925-932.
50. Erenus, M.; Yücelten, D.; Durmusoglu, F.; Gürbüz, O. Comparison of finasteride versus spironolactone in the treatment of idiopathic hirsutism. Fertil. Steril., 1997, 68, 1000-1003.
51. Erenus, M.; Yücelten, D.; Gürbüz, O; Durmusoglu, F.; Pekin, S. Comparison of spironolactone-oral contraceptive versus cyproterone acetate-estrogen regimens in the treatment of hirsutism. Fertil. Steril., 1996, 66, 216-219.
52. Spritzer, P.M.; Lisboa, K.O.; Mattiello, S.; Lhullier, F. Spironolactone as a single agent for long-term therapy of hirsute patients. Clin. Endocrinol., 2000, 52, 587-594.
53. Batukan, C.; Muderris, I.I.; Ozcelik, B.; Ozturk, A. Comparison of two oral contraceptives containing either drospirenone or cyproterone acetate in the treatment of hirsutism. Gynecol. Endocrinol., 2007, 23, 38-44.
54. Gregoriou, O.; Papadias, K.; Konidaris, S.; Bakalianou, K.; Salakos, N.; Vrachnis, N.; Creatsas, G. Treatment of hirsutism with combined pill containing drospirenolone. Gynecol. Endocrinol., 2008, 24, 220-223.
55. Moghetti, P.; Castello, R.; Negri, C.; Tosi, F.; Magnani, C.M.; Fontanarosa, M.C.; Armanini, D.; Muggeo, M. Flutamide in the treatment of hirsutism: long-term clinical effects, endocrine changes, and androgen receptor behavior. Fertil. Steril., 1995, 64, 511-57.
56. Karakurt, F.; Sahin, I.; Güler, S.; Demirbas, B.; Culha, C.; Serter, R.; Aral, Y.; Bavbek, N. Comparison of the clinical efficacy of flutamide and spironolactone plus ethinyloestradiol/cyproterone acetate in the treatment of hirsutism: a randomised controlled study. Adv. Ther., 2008, 25, 321-328.
57. Unluhizarci, K.; Ozel, D.; Tanriverdi, F.; Karaca, Z.; Kelestimur, F. J. Endocrinol. Invest., 2009, 32, 37-40.
58. Rittmaster, R.S. Finasteride. N. Engl. J. Med., 1994, 330, 120-125.
59. Castello, R.; Tosi, F.; Perrone, F.; Negri, C.; Muggeo, M.; Moghetti, P. Outcome of long-term treatment with the 5 alpha-reductase inhibitor finasteride in idiopathic hirsutism: clinical and hormonal effects during a 1-year course of therapy and 1-year follow-up. Fertil. Steril., 1996, 66, 734-734.
60. Ciotta, L.; Cianci, A.; Calogero, A.E.; Palumbo, M.A.; Marletta, E.; Sciuto, A.; Palumbo, G. Clinical and endocrine effects of finasteride, a 5 alpha-reductase inhibitor, in women with idiopathic hirsutism. Fertil. Steril., 1995, 64, 299-306.
61. Byahan, G.; Bahceci, M.; Demirkol, T.; Ertem, M.; Yalynkaia, A.; Erden, A.C. A comparative study of a gonadotropin-releasing hormone agonist and finasteride on idiopathic hirsutism. Clin. Exp. Obstet. Gynecol., 2000, 27, 203-206.
62. Heiner, J.S.; Greendale, G.A.; Kawakami, A.K.; Lapolt, P.S.; Fisher, M.; Young, D.; Judd, H.L. Comparison of a gonadotropinreleasing hormone agonist and a low dose oral contraceptive given alone or together in the treatment of hirsutism. J. Clin. Endocrinol. Metab., 1995, 80, 3412-3418.
63. Carr, B.R.; Breslau, N.A.; Givens, C.; Byrd, W.; Barnett-Hamm, C.; Marshburn, P.B. Oral contraceptive pills, gonadotropinreleasing hormone agonists, or use in combination for treatment of hirsutism: a clinical research center study. J. Clin. Endocrinol. Metab., 1995, 80, 1169-1178.
64. Pazos, F.; Escobar-Morreale, H.F.; Balsa, J.; Sancho, J.M.; Varela, C. Prospective randomized study comparing the long-acting gonadotropin- releasing hormone agonist triptorelin, flutamide, and cyproterone acetate, used in combination with an oral contraceptive, in the treatment of hirsutism. Fertil. Steril., 1999, 71, 122-128.
65. Carmina, E.; Lobo, R.A. Gonadotrophin-releasing hormone agonist therapy for hirsutism is as effective as high dose cyproterone acetate but results in a longer remission. Hum. Reprod., 1997, 12, 663-666.
66. Mansfield, R.; Galea, R.; Brincat, M.; Hole, D.; Mason, H. Metformin has direct effects on human ovarian steroidogenesis. Fertil. Steril., 2003, 79, 956-962.
67. Harborne, L.; Fleming, R.; Lyall, H.; Normann, J.; Sattar, N. Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome. Lancet, 2003, 361, 1894-1901.
68. Tang, T.; Lord, J.M.; Norman, R.J.; Yasmin, E.; Balen, A.H. Withdrawn: insulin-sensitising drugs for polycystic ovary syndrome. Cochrane Database Syst. Rev., 2009, 9, CD003053.
69. Yilmaz, M.; Karacoc, A.; Törüner, F.B.; Cakir, N.; Tiras, B.; Ayvar, G.; Arslan, M. The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome. Gynecol. Endocrinol., 2005, 21, 154-160.
70. Costello, M.F.; Shrestha, B.; Eden, J.; Johnsion, N.D.; Sjoblom, P. Metformin versus oral contraceptive pill in polycystic ovary syndrome: a Cochrane review. Hum. Reprod., 2007, 22, 1200-1209.
71. Nissen, S.E.; Wolski, K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med., 2007, 356, 2457-2471.
72. Rittmaster, R.S.; Givner, M.L. Effect of daily and alternate day low dose prednisone on serum cortisol and adrenal androgens in hirsute women. J. Clin. Endocrinol. Metab., 1988, 67, 400-403.
73. Spritzer, P.; Billaud, L.; Thalabard, J.C.; Birman, P.; Mowszowics, I.; Raux-Demay, M.C.; Clair, F.; Kuttenn, F.; Mauvais-Jarvis, P. Cyproterone acetate versus hydrocortisone treatment in late-onset adrenal hyperplasia. J. Clin. Endocrinol. Metab., 1990, 70, 642-646.
74. Bratoeff, E.; Cabeza, M.; Ramirez, E.; Heuze, Y.; Flores, E. Recent advances in the chemistry and pharmacological activity of new steroidal antiandrogens and 5 alpha-reductase inhibitors. Curr. Med. Chem., 2005; 12, 927-943.
75. Pèrez-Ornelas, V.; Cabeza, M.; Bratoeff, E.; Heuze, I.; Sanchez, M.; Ramirez, E.; Naranjo-Rodriguez, E. New 5α-reductase inhibitors: in vitro and in vivo effects. Steroids, 2005, 70, 217-224.
76. Day, J.M.; Tutill, H.J.; Purohit, A.; Reed, M.J. Design and validation of specific inhibitors of 17β-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis. Endocr. Relat. Cancer, 2008, 15, 665-692.
77. Poirier, D. Advances in development of inhibitors of 17beta hydroxysteroid dehydrogenases. Anticancer Agents Med. Chem., 2009, 9, 642-660.
78. van Hylckama Vlieg, A.; Helmerhorst, F.M.; Vandenbroucke, J.P.; Doggen, C.J.M.; Rosendaal, F.R. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progesterone type: results of the MEGA case-control study. BMJ, 2009, 339, b2921.